Active Ingredient History

  • Now
Cefprozil is a 2nd generation cephalosporin that is FDA approved for the treatment of mild to moderate infections of upper respiratory tract, lower respiratory tract, and uncomplicated skin and skin-structure infections. Cefprozil, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Common adverse reactions include diarrhea, nausea, vomiting, dizziness, abdominal pain and vaginitis. Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics. Concomitant administration of probenecid doubled the AUC for cefprozil.   NCATS

  • SMILES: CC=CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C2=O)C(=O)O
  • Mol. Mass: 389.43
  • ALogP: 0.71
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$0.5892 - $1.7438
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

7-(2-amino-2-(4-hydroxyphenyl)acetamido)-3-(propenyl)-3-cephem-4-carboxylic acid monohydrate | arzimol | bmy 28100 | bmy-28100 | bmy-28100-03-800 | brisoral | cefprozil | cefprozil anhydrous | cefprozile | cefprozil hydrate | cefprozil monohydrate | cefprozilo | cefprozilum | cefzil | cephprozyl | procef


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue